Quantum Genomics Quantum Genomics
  • Company
    • Management
    • Board of directors
    • Inventors
    • Scientific and clinical advisory board
    • Strategy
  • Science
    • Pipeline
      • Firibastat – First-in-class – hypertension as monotherapy
      • Best-in-class – optimized treatment of hypertension and heart failure
      • Hypertension in combination
      • Firibastat – First-in-class – heart failure
    • The BAPAIs
    • Scientific Publications
  • Did you know that ?
    • Did you know that ?
    • High blood pressure
    • Heart failure
  • Investors
    • Press releases
    • Financial documents
      • Annual information
      • Semi-annual information
      • Other regulated informations
    • Investors presentations
    • Equity research
    • Shareholder letter
    • General meetings
    • Shareholding
    • Governance
    • Financial calendar
    • Contacts
  • News & Media
    • Press releases
    • Press/Audio
    • Videos
  • Contact us
  • Français
News

Testimony of Denis, shareholder since 2016 (in French)

Quantum on 27 July 2021

Testimony of Denis, shareholder since 2016 (in French)

See the video

 

Previous Post (p) First patient enrolled in REFREH study
Next Post (n) Quantum Genomics Announces Publication of a New Scientific Article Featuring QGC606
Quantum 2021-07-27T17:30:11+02:00
About

Quantum Genomics is a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, especially high blood pressure and heart failure.

Contact us

33 rue Marbeuf
75008 Paris

[email protected]
+33(0)1 85 34 77 70

Write us

Quick access
  • Strategy
  • Pipeline
  • Did you know that ?
  • Scientific Publications
Search

 

© 2019 Quantum Genomics - Legal notice - Website terms and conditions

  • Company
    • Management
    • Board of directors
    • Inventors
    • Scientific and clinical advisory board
    • Strategy
  • Science
    • Pipeline
      • Firibastat – First-in-class – hypertension as monotherapy
      • Best-in-class – optimized treatment of hypertension and heart failure
      • Hypertension in combination
      • Firibastat – First-in-class – heart failure
    • The BAPAIs
    • Scientific Publications
  • Did you know that ?
    • Did you know that ?
    • High blood pressure
    • Heart failure
  • Investors
    • Press releases
    • Financial documents
      • Annual information
      • Semi-annual information
      • Other regulated informations
    • Investors presentations
    • Equity research
    • Shareholder letter
    • General meetings
    • Shareholding
    • Governance
    • Financial calendar
    • Contacts
  • News & Media
    • Press releases
    • Press/Audio
    • Videos
  • Contact us
  • Français
  • Blog
  • Home
  • Contact us